Kimberly A. Chapman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kimberly A. Chapman has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Parith Wongkittichote
8 shared publications- Marshall L. Summar
George Washington University, CEO, Uncommon Cures Washington DC USA
5 shared publications Elena Pumbo
4 shared publications- Dina J. Zand
Division of Genetics and Metabolism, Children's National Medical Center, 111 Michigan Avenue, N.W., Washington D.C. 20010, USA
3 shared publications Nicholas Ah Mew
Division of Genetics and Metabolism, Children’s National Health System, Washington, DC, USA
3 shared publications- Charles J. Billington
Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455-0356, USA
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Death Secondary to Brain Herniation in Classic MSUD Patients: A Case Series From One Center
Maple Syrup Urine Disease (MSUD) is an inborn error of metabolism associated with defects in the branched‐chain alpha‐keto acid dehydrogenase complex. Despite careful management, patients may experience metabolic decompensation, elevation of leucine levels, cerebral edema, brain herniation, and death. Two populations have been reported to be the most affected: Mennonite and Ashkenazi Jewish. There are three genes associated with this condition, with DBT being the least frequently involved and usually associated with milder or thiamine‐responsive MSUD. We present four patients, three of Salvadoran and one of Afghan ancestry, diagnosed with classic MSUD who developed cerebral edema, herniated, and died despite aggressive medical management. All patients had pathogenic variants in the DBT gene and were not thiamine‐responsive. They all presented with elevated plasma leucine levels that were not their highest recorded after diagnosis. Decompensation in an MSUD patient should be approached with extreme caution, considering that brain edema can progress very rapidly to brain herniation and death, especially since there are no reliable biochemical markers that can predict this fatal outcome. The phenotype and genotype of classic MSUD need to be described more thoroughly, since they can have a more severe presentation and higher mortality rate than previously reported and might be misleading to the treating clinician when genetic testing results are of uncertain significance. Our cohort presents four patients of non‐Mennonite or Ashkenazi Jewish descent with fatal brain herniation occurring rapidly without being preceded by their highest plasma leucine peak registered, significant ketonuria, elevated anion gap, and/or hyponatremia on admission. This highlights the importance of studying different populations affected by MSUD and considering liver transplantation as the potential best treatment option for certain patients.
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Open AccessDeath Secondary to Brain Herniation in Classic MSUD Patients: A Case Series From One Center
Maple Syrup Urine Disease (MSUD) is an inborn error of metabolism associated with defects in the branched‐chain alpha‐keto acid dehydrogenase complex. Despite careful management, patients may experience metabolic decompensation, elevation of leucine levels, cerebral edema, brain herniation, and death. Two populations have been reported to be the most affected: Mennonite and Ashkenazi Jewish. There are three genes associated with this condition, with DBT being the least frequently involved and usually associated with milder or thiamine‐responsive MSUD. We present four patients, three of Salvadoran and one of Afghan ancestry, diagnosed with classic MSUD who developed cerebral edema, herniated, and died despite aggressive medical management. All patients had pathogenic variants in the DBT gene and were not thiamine‐responsive. They all presented with elevated plasma leucine levels that were not their highest recorded after diagnosis. Decompensation in an MSUD patient should be approached with extreme caution, considering that brain edema can progress very rapidly to brain herniation and death, especially since there are no reliable biochemical markers that can predict this fatal outcome. The phenotype and genotype of classic MSUD need to be described more thoroughly, since they can have a more severe presentation and higher mortality rate than previously reported and might be misleading to the treating clinician when genetic testing results are of uncertain significance. Our cohort presents four patients of non‐Mennonite or Ashkenazi Jewish descent with fatal brain herniation occurring rapidly without being preceded by their highest plasma leucine peak registered, significant ketonuria, elevated anion gap, and/or hyponatremia on admission. This highlights the importance of studying different populations affected by MSUD and considering liver transplantation as the potential best treatment option for certain patients.
- Open Access
- 5 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
A home for rare disease: the creation of the NORD centers of excellence
Rare disorders, defined as having fewer than 200,000 affected individuals in the United States, present unique challenges due to their rarity. Few single institutions possess the comprehensive experience, clinical expertise, advocacy, and research background necessary to optimize patient care for those affected by a variety of rare disorders. The National Organization for Rare Disorders (NORD ® ), an umbrella organization advocating for all rare disease groups, has designated 49 Rare Disease Centers of Excellence (RD CoE), representing more than 170 academic medical and research institutions. These designated centers demonstrate broad rare disease capacity across facilities, clinical expertise, research, advocacy, and experience in managing rare diseases. NORD’s RD CoE framework fosters collaboration aimed at improving care for individuals with rare diseases. Given the complexities of rare diseases, the Network provides a structure for connecting institutions and is developing infrastructure intended to facilitate multi-institutional studies, appropriate data sharing, collaborative protocol development, and broader participation in rare disease clinical research. It also connects academic centers with patient organizations and other partners to support research, education, and therapeutic implementation. This paper describes the creation, selection process, governance, and early collaborative infrastructure of the NORD RD CoE Network.
- 5 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Open AccessA home for rare disease: the creation of the NORD centers of excellence
Rare disorders, defined as having fewer than 200,000 affected individuals in the United States, present unique challenges due to their rarity. Few single institutions possess the comprehensive experience, clinical expertise, advocacy, and research background necessary to optimize patient care for those affected by a variety of rare disorders. The National Organization for Rare Disorders (NORD ® ), an umbrella organization advocating for all rare disease groups, has designated 49 Rare Disease Centers of Excellence (RD CoE), representing more than 170 academic medical and research institutions. These designated centers demonstrate broad rare disease capacity across facilities, clinical expertise, research, advocacy, and experience in managing rare diseases. NORD’s RD CoE framework fosters collaboration aimed at improving care for individuals with rare diseases. Given the complexities of rare diseases, the Network provides a structure for connecting institutions and is developing infrastructure intended to facilitate multi-institutional studies, appropriate data sharing, collaborative protocol development, and broader participation in rare disease clinical research. It also connects academic centers with patient organizations and other partners to support research, education, and therapeutic implementation. This paper describes the creation, selection process, governance, and early collaborative infrastructure of the NORD RD CoE Network.
- Open Access
- 14 October 2026
- Published by Wiley in JPGN Reports
Nudix hydrolase 15 deficiency and azathioprine toxicity in a liver transplant recipient: A case report
Thiopurines, such as azathioprine (AZA), are among the immunosuppressants used to prevent allograft rejection. Thiopurines are metabolized by thiopurine S‐methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) enzymes, and their functions are highly influenced by genetic variation. We present a 6‐year‐old female with recurrent acute cellular rejection and steroid‐induced glaucoma due to high‐dose corticosteroid therapy. Consequently, AZA was incorporated into her calcineurin‐inhibitor‐based regimen to reduce steroid dose. Within 33 days of initiating AZA, alopecia and pancytopenia developed despite confirmed TPMT enzyme activity with normal phenotype and low 6‐Thioguanine and 6‐Methylmercaptopurine levels in the blood. Pharmacogenomic analysis revealed an NUDT15 *3/*3 genotype, indicating two “no function” alleles, classified as NUDT15 poor metabolizer at high risk of myelosuppression with standard thiopurine doses. Liver donor pharmacogenomic testing was not performed. This case highlights the consideration of pharmacogenomic testing for recipient and donor prior to thiopurine use in liver‐transplant recipients.
- 14 October 2026
- Published by Wiley in JPGN Reports
Open AccessNudix hydrolase 15 deficiency and azathioprine toxicity in a liver transplant recipient: A case report
Thiopurines, such as azathioprine (AZA), are among the immunosuppressants used to prevent allograft rejection. Thiopurines are metabolized by thiopurine S‐methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) enzymes, and their functions are highly influenced by genetic variation. We present a 6‐year‐old female with recurrent acute cellular rejection and steroid‐induced glaucoma due to high‐dose corticosteroid therapy. Consequently, AZA was incorporated into her calcineurin‐inhibitor‐based regimen to reduce steroid dose. Within 33 days of initiating AZA, alopecia and pancytopenia developed despite confirmed TPMT enzyme activity with normal phenotype and low 6‐Thioguanine and 6‐Methylmercaptopurine levels in the blood. Pharmacogenomic analysis revealed an NUDT15 *3/*3 genotype, indicating two “no function” alleles, classified as NUDT15 poor metabolizer at high risk of myelosuppression with standard thiopurine doses. Liver donor pharmacogenomic testing was not performed. This case highlights the consideration of pharmacogenomic testing for recipient and donor prior to thiopurine use in liver‐transplant recipients.
- 1 May 2026
- Published by Springer Nature
- p. 331-336
Maple Syrup Urine Diseases: Organic Acidemias
- 1 May 2026
- Published by Springer Nature
- p. 261-265
Mitochondrial Disease
- Open Access
Pathogenic variants in TMEM184B cause a neurodevelopmental syndrome associated with alteration of metabolic signaling
Transmembrane protein 184B (TMEM184B) is an endosomal 7-pass transmembrane protein with evolutionarily conserved roles in synaptic structure and axon degeneration. We report six pediatric cases who have de novo heterozygous variants in TMEM184B ; five individuals harbor a rare missense variant and one individual has an mRNA splice site change. This cohort is unified by overlapping neurodevelopmental deficits including developmental delay, corpus callosum hypoplasia, seizures, and/or microcephaly. TMEM184B is predicted to contain a pore domain wherein four of five human disease-associated missense variants cluster. Structural modeling suggests that all missense variants alter TMEM184B protein stability. To understand the contribution of TMEM184B to neural development in vivo , we knocked down the TMEM184B ortholog in zebrafish and observed microcephaly and reduced anterior commissural axons, aligning with symptoms of affected individuals. Ectopic expression of TMEM184B c.550A>G; p.Lys184Glu and c.484G>A; p.Gly162Arg variants cause reduced head size and body length, indicating dominant effects, while three other variants show haploinsufficiency. None of the variants are able to rescue the knockdown phenotype. Human induced pluripotent stem cells (iPSC) with monoallelic production of p.Lys184Glu show mRNA disruptions in key metabolic pathways including those controlling mechanistic target of rapamycin (mTOR) activity. Expression of p.Lys184Glu and c.863G>C; p.Gly288Ala increased apoptosis in cell lines and p.Lys184Glu increased nuclear localization of transcription factor EB (TFEB), consistent with a cellular starvation state. Together, our data indicate that TMEM184B variants cause cellular metabolic disruption and result in abnormal neural development.
Open AccessPathogenic variants in TMEM184B cause a neurodevelopmental syndrome associated with alteration of metabolic signaling
Transmembrane protein 184B (TMEM184B) is an endosomal 7-pass transmembrane protein with evolutionarily conserved roles in synaptic structure and axon degeneration. We report six pediatric cases who have de novo heterozygous variants in TMEM184B ; five individuals harbor a rare missense variant and one individual has an mRNA splice site change. This cohort is unified by overlapping neurodevelopmental deficits including developmental delay, corpus callosum hypoplasia, seizures, and/or microcephaly. TMEM184B is predicted to contain a pore domain wherein four of five human disease-associated missense variants cluster. Structural modeling suggests that all missense variants alter TMEM184B protein stability. To understand the contribution of TMEM184B to neural development in vivo , we knocked down the TMEM184B ortholog in zebrafish and observed microcephaly and reduced anterior commissural axons, aligning with symptoms of affected individuals. Ectopic expression of TMEM184B c.550A>G; p.Lys184Glu and c.484G>A; p.Gly162Arg variants cause reduced head size and body length, indicating dominant effects, while three other variants show haploinsufficiency. None of the variants are able to rescue the knockdown phenotype. Human induced pluripotent stem cells (iPSC) with monoallelic production of p.Lys184Glu show mRNA disruptions in key metabolic pathways including those controlling mechanistic target of rapamycin (mTOR) activity. Expression of p.Lys184Glu and c.863G>C; p.Gly288Ala increased apoptosis in cell lines and p.Lys184Glu increased nuclear localization of transcription factor EB (TFEB), consistent with a cellular starvation state. Together, our data indicate that TMEM184B variants cause cellular metabolic disruption and result in abnormal neural development.
- Open Access
A novel, high throughput, and low-cost method for the detection of 40 amines relevant to inborn errors of metabolism, in under 60 minutes, using reverse phase high performance liquid chromatography
Objectives: An assessment of amino acid and amine concentrations is important for the diagnosis and management of inborn errors of metabolism (IEMs). Methods exist that measure these biologically important metabolites but are cost-prohibitive and/or time consuming. We therefore sought to develop a novel methodology, applicable to IEMs, that is both high-throughput and low cost. Methods: Previously, we developed a methodology for rapid, repeatable, and cost-efficient separation of approximately 20 amines as a proof of concept and now expand it to amines relevant to IEMs. We describe our separation methodology using reverse phase high performance liquid chromatography with ultraviolet-visible spectrum absorbance paired with precolumn derivatization with o -phthaladehyde. Results: We show reproducibility via concentration assessments, in triplicate, for each amine. We assess amines in prepared standard solutions and in biologic samples from patients with IEMs. We also detected and assessed the amino group containing compounds oxidized and reduced glutathione and ammonia. Validation was established using absolute area under the curve (AUC) and via comparison using a single internal standard. Conclusions: We report good separation of 40 primary amino group containing metabolites, in a single, less than 60-minute run. This rapid, low cost, and accurate methodology only requires a small volume of sample and can greatly increase availability and access. Finally, the numerous disease associated amines (ie homocitrulline, trimethyllysine, alloisoleucine) and unique compounds detected in our single run has broad research and clinical utility and can increase efficiency, important as the need for analysis of amines grows globally.
Open AccessA novel, high throughput, and low-cost method for the detection of 40 amines relevant to inborn errors of metabolism, in under 60 minutes, using reverse phase high performance liquid chromatography
Objectives: An assessment of amino acid and amine concentrations is important for the diagnosis and management of inborn errors of metabolism (IEMs). Methods exist that measure these biologically important metabolites but are cost-prohibitive and/or time consuming. We therefore sought to develop a novel methodology, applicable to IEMs, that is both high-throughput and low cost. Methods: Previously, we developed a methodology for rapid, repeatable, and cost-efficient separation of approximately 20 amines as a proof of concept and now expand it to amines relevant to IEMs. We describe our separation methodology using reverse phase high performance liquid chromatography with ultraviolet-visible spectrum absorbance paired with precolumn derivatization with o -phthaladehyde. Results: We show reproducibility via concentration assessments, in triplicate, for each amine. We assess amines in prepared standard solutions and in biologic samples from patients with IEMs. We also detected and assessed the amino group containing compounds oxidized and reduced glutathione and ammonia. Validation was established using absolute area under the curve (AUC) and via comparison using a single internal standard. Conclusions: We report good separation of 40 primary amino group containing metabolites, in a single, less than 60-minute run. This rapid, low cost, and accurate methodology only requires a small volume of sample and can greatly increase availability and access. Finally, the numerous disease associated amines (ie homocitrulline, trimethyllysine, alloisoleucine) and unique compounds detected in our single run has broad research and clinical utility and can increase efficiency, important as the need for analysis of amines grows globally.
- Open Access
- 14 August 2023
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 36, 100999
Dental complications in homocystinurias
- 14 August 2023
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 36, 100999
Open AccessDental complications in homocystinurias
- Open Access
- 7 July 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (9) , 2738-2749
Genomic and biochemical analysis of repeatedly observed variants in DBT in individuals with maple syrup urine disease of Central American ancestry
Maple syrup urine disease (MSUD) is an intoxication‐type inherited metabolic disorder in which hyperleucinemia leads to brain swelling and death without treatment. MSUD is caused by branched‐chain alpha‐ketoacid dehydrogenase deficiency due to biallelic loss of the protein products from the genes BCKDHA, BCKDHB, or DBT, while a distinct but related condition is caused by loss of DLD. In this case series, eleven individuals with MSUD caused by two pathogenic variants in DBT are presented. All eleven individuals have a deletion of exon 2 (delEx2, NM_001918.3:c.48_171del); six individuals are homozygous and five individuals are compound heterozygous with a novel missense variant (NM_001918.5:c.916 T > C [p.Ser306Pro]) confirmed to be in trans. Western Blot indicates decreased amount of protein product in delEx2;c.916 T > C liver cells and absence of protein product in delEx2 homozygous hepatocytes. Ultrahigh performance liquid chromatography–tandem mass spectrometry demonstrates an accumulation of branched‐chain amino acids and alpha‐ketoacids in explanted hepatocytes. Individuals with these variants have a neonatal‐onset, non‐thiamine‐responsive, classical form of MSUD. Strikingly, the entire cohort is derived from families who immigrated to the Washington, DC, metro area from Honduras or El Salvador suggesting the possibility of a founder effect.
- 7 July 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (9) , 2738-2749
Open AccessGenomic and biochemical analysis of repeatedly observed variants in DBT in individuals with maple syrup urine disease of Central American ancestry
Maple syrup urine disease (MSUD) is an intoxication‐type inherited metabolic disorder in which hyperleucinemia leads to brain swelling and death without treatment. MSUD is caused by branched‐chain alpha‐ketoacid dehydrogenase deficiency due to biallelic loss of the protein products from the genes BCKDHA, BCKDHB, or DBT, while a distinct but related condition is caused by loss of DLD. In this case series, eleven individuals with MSUD caused by two pathogenic variants in DBT are presented. All eleven individuals have a deletion of exon 2 (delEx2, NM_001918.3:c.48_171del); six individuals are homozygous and five individuals are compound heterozygous with a novel missense variant (NM_001918.5:c.916 T > C [p.Ser306Pro]) confirmed to be in trans. Western Blot indicates decreased amount of protein product in delEx2;c.916 T > C liver cells and absence of protein product in delEx2 homozygous hepatocytes. Ultrahigh performance liquid chromatography–tandem mass spectrometry demonstrates an accumulation of branched‐chain amino acids and alpha‐ketoacids in explanted hepatocytes. Individuals with these variants have a neonatal‐onset, non‐thiamine‐responsive, classical form of MSUD. Strikingly, the entire cohort is derived from families who immigrated to the Washington, DC, metro area from Honduras or El Salvador suggesting the possibility of a founder effect.
- 21 March 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (3) , S349
OP017: Triheptanoin for the treatment of Long-Chain Fatty Acid Disorders (LC-FAOD): Final results of an open-label, long-term extension study
- 21 March 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (3) , S349
OP017: Triheptanoin for the treatment of Long-Chain Fatty Acid Disorders (LC-FAOD): Final results of an open-label, long-term extension study